Levy et al. “Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer – a preliminary report” (Thromb Haemost 2009; 102.4)

Appendix

**Inclusion Criteria:** Informed consent obtained before any trial-related activities; age between 35 and 75 years of age; undergoing first myocardial revascularisation; adequate renal and hepatic function defined as creatinine ≤1.4 \(\text{mg/dl}\), bilirubin ≤1.5 times upper limit of normal, alkaline phosphatase ≤2 times upper limit of normal and AST ≤1.5 times upper limit of normal; a haematocrit ≥34% for females and 39% for males and haemoglobin ≥11.8 \(\text{g/dl}\) for females and 13.5 \(\text{g/dl}\) for males; a negative serum pregnancy test within 3 days of enrolment if female and of child-bearing potential; agreement to use a medically accepted form of contraception if applicable; a negative history for drug abuse.

**Exclusion Criteria:** Previous participation (randomisation and dosing) in the trial; known antibodies or hypersensitivity to FXIII; known hereditary bleeding diathesis or coagulopathy; known allergy to yeast or yeast-derived proteins; need for an emergent (<24-hour) myocardial revascularisation procedure; undergoing a procedure that requires deep hypothermic circulatory arrest <28°C, or had deep hypothermic cardiac arrest <32°C during current procedure; any surgical procedure in the 30 days prior to enrolment (excluding angiogram); a previous history of autoimmune disorder involving autoantibodies, e.g., systemic lupus erythematosus; a history of cerebrovascular event (including thrombotic or haemorrhagic stroke or transient ischaemic attack) and/or extra-myocardial thromboembolic events, e.g., deep vein thrombosis or pulmonary embolus; history or family history of heritable coagulopathy, including Factor V Leiden, Protein C deficiency, Protein S deficiency; type 1 diabetes or type 2 diabetes requiring insulin treatment at the time of screening, and/or having a history of diabetic retinopathy; a history of peripheral vascular disease requiring surgical correction, including carotid endarterectomy (CEA) or femoral-popliteal bypass, or is currently experiencing claudication; a body mass index (BMI) ≥37; a history of heparin-induced thrombocytopenia; acute myocardial infarction (MI) <24 hours prior to surgery, or has suspected or confirmed intra-operative MI; pre-operative (within 30 days) transfusion of any blood and/or blood product; atrial fibrillation or history of atrial fibrillation; receipt of clopidogrel (Plavix®) <5 days prior to surgery; receipt of abciximab (ReoPro®) <24 hours prior to surgery; receipt of other GP Ib/IIa inhibitors <12 hours prior to surgery; receipt of tPA or fibrinolitics <24 hours prior to surgery; receipt of low molecular weight heparin (LMWH) within 3 days of surgery; preoperative heparin exposure for >3 days; preoperative heparin exposure for ≤3 days and a prior history of therapeutic heparin exposure (defined as subcutaneous or intravenous administration) within the preceding 6 months; receipt or expected receipt of aprotinin (Trasylo®), epsilon-amino caproic acid (Amicar®), tranexamic acid (Cyklokapron®) or factor VIIa (NovoSeven®); a preoperative (within 30 days) ejection fraction of <30% or current signs and symptoms of congestive heart failure; haemodynamic instability during or following bypass requiring placement of a left ventricular assist device or intra-aortic balloon pump or administration of ≥2 inotropic agents, excluding vasopressors; requirement for surgical procedures in addition to myocardial revascularisation, e.g., valve repair or replacement; ventricular arrhythmia post-CPB cannula removal that requires therapeutic intervention; prior treatment with any experimental agent within 30 days prior to enrolment; prior treatment with rFXIII; pregnancy, breast feeding or intention of becoming pregnant; concurrent serious chronic or acute illness or infection, as per the investigator’s judgment; medical, social or psychosocial factors expected to impact upon compliance or safety; weight >140 kg.